Spinal Muscular Atrophy Market Outlook

1
Spinal Muscular Atrophy Market

2
Report Description and Highlights
Analyst View Spinal muscular atrophy disease
incidence of approximately 1 in 10,000
newborns and a prevalence of approximately 1 to 2
per 100,000 persons, globally.  Spinal muscular
atrophy is basically 4 types  Type 1, Type 2,
Type 3 and Type 4. Most patients suffers with
Spinal muscular atrophy type 1. According to
Renub Research Spinal Muscular Atrophy Market is
anticipated to grow at a CAGR of 14.29 percent in
future. This double digit growth rate will happen
due to expected launch of new drugs, better
reimbursement options and decline in drugs
prices.      Renub Research report
titled Spinal Muscular Atrophy Market Global
Forecast by Countries (United States, United
Kingdom, France, Germany, Spain, Italy Japan),
Drugs (Spinraza, AVXS-101, CK2127107, RG7916,
Olesoxime LMI070), Companies (Biogen Inc.,
Roche AG, Novartis AG, Cytokinetics Inc) studies
the global spinal muscular atrophy market and
provides an all-encompassing analysis of the key
growth drivers and challenges, market trends, key
players and their projections for the future.



3
Spinal Muscular Atrophy Market New Drugs are
expected to launch in recent years
Spinal muscular atrophy is a disease that causes
muscle weakness which mostly appears in newborn
children. Spinal Muscular Atrophy (SMA) type 1
develop in less than 6 months of newborn children
in which patients are not in position to sit in
their lifetime and normally they die within 6
months.  In spinal muscular atrophy type 2,
patients can sit but cannot walk. Type 2 is
developed between 6-18 months of the new born
children. Spinal muscular atrophy Type 3 patients
can sit and walk and it developed when children
age is less than 18 months. Spinal muscular
atrophy Type 4 can develop during the
adulthood.   Spinal Muscular Atrophy Market New
Drugs are expected to launch in recent years At
present only Biogens Spinraza is approved for
the treatment of spinal muscular atrophy patients
in the various parts of the globe such as United
States, Europe, and Japan etc.  Other companies
are also working for new drugs development and
they hope to enter in the market place very soon
as their drugs are in Phase III clinical trials.
  Read more here https//www.renub.com/spinal-m
uscular-atrophy-market-p.php

4
Spinal Muscular Atrophy Patient Population Share
Global Current Forecast for Spinal Muscular
Atrophy Patient Population Share (Percent), 2017
2026

Source Renub Research Analysis Note These are
dummy figures actual data given in the report
5
Spinal muscular atrophy market by country has
been segmented into US, UK, France, Germany,
Spain, Italy Japan
By Country - Market Segmentation Spinal muscular
atrophy market by country has been segmented into
United States, United Kingdom, France, Germany,
Spain, Italy and Japan. United States is a
leading market place due to increasing number of
treated Patients, favorable reimbursement
policies and increase in healthcare
expenditure. By Total Treated Patients -
Population Segmentation Spinal muscular atrophy
Total Treated Patients by country has been
segmented into United States, United Kingdom,
France, Germany, Spain, Italy and Japan. United
States is dominating in the treated SMA patients
globally.  By Drugs - Market Segmentation The
report by Renub Research studies the spinal
muscular atrophy six drugs (Spinraza, AVXS-101,
CK2127107, RG7916, Olesoxime LMI070) details
with present and estimated global sales. Want
more Information about this market? Request a
free sample copy https//www.renub.com/contactus
.php

6
Spinal Muscular Atrophy Treated Patients (Number)
Global Current Forecast for Spinal Muscular
Atrophy Treated Patients (Number), 2017 2026

Source Renub Research Analysis Note These are
dummy figures actual data given in the report
7
Countries, Drugs and Companies covered in this
report
Country Covered     United States    United
Kingdom    France     Germany    Italy   
 Spain    Japan Drugs Details Covered
    Spinraza    AVXS-101    CK2127107  
 RG7916    Olesoxime    LMI070 Company
Covered     Biogen Inc.    Roche AG  
 Novartis AG    Cytokinetics Inc

  Browse Related Report Multiple Sclerosis
Market US Generic Drugs Market Contact Us Tel
1-678-302-0700 (US), 91-120-421-9822
(INDIA) Email info_at_renub.com